Amplyx Pharmaceuticals

Fast Track designation granted to fosmanogepix for seven indications

10 September 2019 | By Rachael Harper (European Pharmaceutical Review)

Both the intravenous and oral formulations of the antifungal candidate, fosmanogepix, have been granted Fast Track designation by the FDA.